Revvity launches type 1 diabetes screening kit in Europe

WALTHAM, Mass. - Revvity Inc., a company listed on the NYSE under the ticker RVTY, has announced the launch of the GSP T1D 3plex kit. This new multiplex autoantibody detection solution is designed for screening programs that aim to identify children at risk of developing type 1 diabetes before symptoms manifest. Certified under CE-IVDR standards, the kit utilizes capillary dried blood spots for sample collection and is processed through Revvity’s GSP instrument, which is utilized in newborn screening programs.

According to a company press release, the system can identify at-risk individuals months or years prior to symptom onset. The introduction of the GSP T1D 3plex kit represents a significant advancement in Revvity's efforts to expand its offerings in child health screening. Anna Godenhjelm, Revvity's vice president and general manager for reproductive health, stated that the kit is tailored for the development of national type 1 diabetes screening programs.

Type 1 diabetes is typically diagnosed after beta-cell damage has occurred, sometimes leading to diabetic ketoacidosis episodes. Revvity will discuss its type 1 diabetes testing solutions, developed in partnership with Sanofi, at the European Association for the Study of Diabetes conference taking place from September 28 to October 2 in Milan, Italy.

The GSP T1D 3plex kit will be available in Europe and other regions that accept CE IVD-marked products, though it is important to note that the product has not received clearance from the U.S. Food and Drug Administration. In 2025, Revvity reported revenue of $2.9 billion and employs around 11,000 individuals. The company specializes in health science solutions and technologies, serving customers in pharmaceuticals, biotechnology, diagnostic laboratories, academia, and government sectors.

Revvity is also a component of the S&P 500 index. This report, which was created with the assistance of artificial intelligence and reviewed by an editor, provides a comprehensive overview of the company's recent developments.